EUVIMEDEUVIMED entdecken
Crossref

Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis

Jaleh Fallah iD, Haley Gittleman, Chana Weinstock, Elaine Chang iD, Sundeep Agrawal, Shenghui Tang, Richard Pazdur, Paul G Kluetz iD, Daniel L Suzman, Laleh Amiri-Kordestani

JNCI: Journal of the National Cancer Institute · 2024

DOI: 10.1093/jnci/djae066 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2024. Verfasst von Jaleh Fallah und 9 weiteren Autor:innen. Beteiligte Einrichtung: Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA. Hauptthemen laut MEDLINE: Nephrectomy, Immune Checkpoint Inhibitors, Kidney Neoplasms, Cytoreduction Surgical Procedures. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This pooled analysis of patient-level data from trials evaluated the clinical outcomes of patients with metastatic renal cell carcinoma with or without cytoreductive nephrectomy before a combination of immune checkpoint inhibitor and antiangiogenic therapy.

Methods

Data from 5 trials of immune checkpoint inhibitors plus antiangiogenic therapy were pooled. Only patients with stage 4 disease at initial diagnosis were included to ensure that nephrectomy was performed for cytoreductive purposes and not to previously treat an earlier stage of disease. The effect of cytoreductive nephrectomy before immune checkpoint inhibitor therapy on outcomes was evaluated using the Kaplan-Meier method and a Cox proportional hazards regression model, adjusted for age, sex, risk group, performance status, and the presence of sarcomatoid differentiation.

Results

A total of 981 patients were included. The estimated median progression-free survival with and without nephrectomy was 15 and 11 months, respectively; the adjusted hazard ratio was 0.71 (95% confidence interval = 0.59 to 0.85). The estimated median overall survival with and without nephrectomy was 46 and 28 months, respectively; the adjusted hazard ratio was 0.63 (95% confidence interval = 0.51 to 0.77). Objective response was 60% of patients with vs 46% of patients without cytoreductive nephrectomy.

Conclusions

Patients with metastatic renal cell carcinoma who undergo cytoreductive nephrectomy before immune checkpoint inhibitor plus antiangiogenic therapy had improved outcomes compared with patients without cytoreductive nephrectomy. Selection factors for cytoreductive nephrectomy may be prognostic and could not be fully controlled for in this retrospective analysis. Prospective determination of and stratification by prior cytoreductive nephrectomy may be considered when designing clinical trials to assess the impact of this factor on prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NephrectomyImmune Checkpoint InhibitorsKidney NeoplasmsCytoreduction Surgical ProceduresCarcinoma, Renal CellUnited States Food and Drug AdministrationHumansUnited StatesMaleFemaleMiddle AgedAgedAngiogenesis InhibitorsAdult

Substanzen

Immune Checkpoint InhibitorsAngiogenesis Inhibitors

Autor:innen und Institutionen

  • Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD, USA.
  • Oncology Center of Excellence, US Food and Drug Administration, Silver Spring, MD, USA.

ORCID-Profile: Jaleh Fallah, Elaine Chang, Paul G Kluetz

Zitieren

APA

Fallah, J., Gittleman, H., Weinstock, C., Chang, E., Agrawal, S., Tang, S., Pazdur, R., Kluetz, P. G., Suzman, D. L., & Amiri-Kordestani, L. (2024). Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae066

Vancouver

Fallah J, Gittleman H, Weinstock C, Chang E, Agrawal S, Tang S, et al. Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis. JNCI: Journal of the National Cancer Institute. 2024. doi:10.1093/jnci/djae066

BibTeX
@article{Fallah2024,
  author = {Fallah, Jaleh and Gittleman, Haley and Weinstock, Chana and Chang, Elaine and Agrawal, Sundeep and Tang, Shenghui and Pazdur, Richard and Kluetz, Paul G and Suzman, Daniel L and Amiri-Kordestani, Laleh},
  title = {Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a US Food and Drug Administration pooled analysis},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2024},
  doi = {10.1093/jnci/djae066}
}
Kostenlos starten →